« Förderinformationen
Fünfter Aufruf der Innovative Medicines Initiative 2 IMI2 veröffentlicht
Termin:
13.10.2015
Fördergeber:
Europäische Kommission : Horizon 2020
Am 09. Juli 2015 wurde der fünfte Aufruf der Innovative Medicines Initiative 2 (IMI2) mit den folgenden Ausschreibungsthemen (Topics) veröffentlicht:
? Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and health technology assessment bodies
? Diabetic kidney disease biomarkers (DKD-BM)
? Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33
? Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)
? Evolving models of patient engagement and access for earlier identification of Alzheimer's disease: phased expansion study
? From ApoE biology to validated Alzheimer's disease targets
Die Einreichungsfrist der Anträge der 1. Stufe ist der 13. Oktober 2015.
Fachliche Ansprechpartner der NKS-L sind Jan Skriwanek, Tel.: 0228-38211677, E-Mail: jan.skriwanek@dlr.de und Dr. Rebecca Breuer, Tel.: 0228-38211705, E-Mail: Rebecca.Breuer@dlr.de.
Weitere Informationen:
www.imi.europa.eu/content/imi-2-call-5-0
? Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and health technology assessment bodies
? Diabetic kidney disease biomarkers (DKD-BM)
? Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33
? Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)
? Evolving models of patient engagement and access for earlier identification of Alzheimer's disease: phased expansion study
? From ApoE biology to validated Alzheimer's disease targets
Die Einreichungsfrist der Anträge der 1. Stufe ist der 13. Oktober 2015.
Fachliche Ansprechpartner der NKS-L sind Jan Skriwanek, Tel.: 0228-38211677, E-Mail: jan.skriwanek@dlr.de und Dr. Rebecca Breuer, Tel.: 0228-38211705, E-Mail: Rebecca.Breuer@dlr.de.
Weitere Informationen:
www.imi.europa.eu/content/imi-2-call-5-0